June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Navigated laser and aflibercept in treatment of branch retinal vein occlusion and macular edema: a 12 months randomized clinical trial
Author Affiliations & Notes
  • Katrine Hartmund Frederiksen
    Department of Ophthalmology, Odense Universitetshospital, Odense, Syddanmark, Denmark
    Department of Clinical Research, Syddansk Universitet Det Sundhedsvidenskabelige Fakultet, Odense, Syddanmark, Denmark
  • Jesper Vestergaard
    Department of Ophthalmology, Odense Universitetshospital, Odense, Syddanmark, Denmark
  • Frederik Nørregaard Pedersen
    Department of Ophthalmology, Odense Universitetshospital, Odense, Syddanmark, Denmark
    Department of Clinical Research, Syddansk Universitet Det Sundhedsvidenskabelige Fakultet, Odense, Syddanmark, Denmark
  • Anna Stage Vergmann
    Department of Ophthalmology, Odense Universitetshospital, Odense, Syddanmark, Denmark
  • Torben Lykke Sørensen
    Department of Ophthalmology, Sjaellands Universitetshospital Roskilde, Roskilde, Sjaelland, Denmark
    Kobenhavns Universitet Sundhedsvidenskabelige Fakultet, Kobenhavn, Denmark
  • Caroline Laugesen
    Department of Ophthalmology, Sjaellands Universitetshospital Roskilde, Roskilde, Sjaelland, Denmark
  • Ryo Kawasaki
    Department of Vision Informatics, Osaka Daigaku Daigakuin Igakukei Kenkyuka Igakubu, Suita, Osaka, Japan
  • Tunde Peto
    School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast Faculty of Medicine Health and Life Sciences, Belfast, Belfast, United Kingdom
  • Jakob Grauslund
    Department of Ophthalmology, Odense Universitetshospital, Odense, Syddanmark, Denmark
    Department of Clinical Research, Syddansk Universitet Det Sundhedsvidenskabelige Fakultet, Odense, Syddanmark, Denmark
  • Footnotes
    Commercial Relationships   Katrine Frederiksen None; Jesper Vestergaard None; Frederik Pedersen None; Anna Vergmann None; Torben Sørensen None; Caroline Laugesen None; Ryo Kawasaki None; Tunde Peto None; Jakob Grauslund None
  • Footnotes
    Support  Danske regioner medicinpuljen, Øjenforeningen Værn om Synet, Synoptikfonden, Toyotafonden A/S, Region Sjællands og Region Syddanmarks forskningspulje, Fabrikant Einar Willumsens mindelegat, Grosserer Christian Andersen og hustru Ingeborg Ovidia Signe Andersen, født Schmidts legat, A.P. Møller Fonden for Lægevidenskabens Fremme and Odense University Hospital PhD Fund.
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 1728 – F0188. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Katrine Hartmund Frederiksen, Jesper Vestergaard, Frederik Nørregaard Pedersen, Anna Stage Vergmann, Torben Lykke Sørensen, Caroline Laugesen, Ryo Kawasaki, Tunde Peto, Jakob Grauslund; Navigated laser and aflibercept in treatment of branch retinal vein occlusion and macular edema: a 12 months randomized clinical trial. Invest. Ophthalmol. Vis. Sci. 2022;63(7):1728 – F0188.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : In branch retinal vein occlusion (BRVO), central retinal laser has to some extend been replaced by angiostatic agents as first line treatment. While these efficiently reduce macular edema and increase visual acuity, the treatment is often inconvenient and expensive. In order to investigate a novel treatment strategy, we aimed to evaluate if combined treatment of aflibercept and navigated central retinal laser could lower injection burden in patients with BRVO and macular edema.

Methods : Forty treatment-naïve patients with BRVO and macular edema were included and randomized 1:1 to three monthly intravitreal injections of 2.0 mg aflibercept with (Group A) or without (Group B) navigated central retinal laser at month three. Patients were followed monthly from month four through 12, and re-treated with aflibercept according to re-treatment criteria: increase in central retinal thickness (CRT) ≥ 20% compared with lowest measurement, or decrease in best corrected visual acuity (BCVA) > 5 Early Treatment Diabetic Retinopathy Study (ETDRS) letters as compared to baseline.

Results : Median age was 69.6 years, 45% were male, median BCVA was 66.6 letters, and median CRT was 541.4 µm, with no difference between groups. Seventy-five percent of patients needed retreatment after month three, and median number of retreatments was one with no difference between groups A and B (71.4% vs 79.0%, p=0.72, and one vs. two, p=0.38). Between baseline and month 12, median BCVA increased 13.0 ETDRS letters and median CRT was reduced by 192 µm with no difference between groups (+12.0 vs. +14.0 ETDRS letters, p=0.30, and -195µm vs. -185µm, p=0.96). Change in central retinal sensitivity, measured by microperimetry, did not differ according to treatment regimen (+2.87dB vs. +3.93 dB, p=0.40).

Conclusions : In a randomized trial of patients with treatment-naïve BRVO and macular edema, we found no difference in efficacy, side effects or treatment-burden when comparing combinational treatment of aflibercept and navigated central laser with aflibercept monotherapy. This may to some extend be explained by a lower than expected need for re-treatment of the intravitreal monotherapy group.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×